Capmatinib
Författaruppgift saknas
Journal missing · review PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för capmatinib. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
31 hitsComplete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report.
Alves de Souza G, Dornellas DMS, Campregher PV, Teixeira CHA, Schvartsman G.
Oncologist · research-article; journal article; case reports · DOI 10.1093/oncolo/oyae106Savolitinib conferred sensitivity in a patient with D1228H mutation-induced capmatinib-resistant MET exon 14 skipping mutated lung adenocarcinoma.
Li X, Lu Y, Zhao J, Yu Y, Tian H, Zhu H, Li W, Xia Y, Chen L.
J Cancer Res Clin Oncol · journal article; case reports; case-report · DOI 10.1007/s00432-024-05920-1Development and validation of an ultra-performance liquid chromatography-tandem mass spectrometry method to quantify the small molecule inhibitors adagrasib, alectinib, brigatinib, capmatinib, crizotinib, lorlatinib, selpercatinib, and sotorasib in human plasma.
Hollander EM, Zimmerman NMC, Piet B, van den Heuvel MM, Burger DM, Te Brake LHM, Ter Heine R.
Biomed Chromatogr · journal article · DOI 10.1002/bmc.5986A novel disposable ultrasensitive sensor based on nanosized ceria uniformly loaded carbon nanofiber nanoceramic film wrapped on pencil graphite rods for electrocatalytic monitoring of a tyrosine kinase inhibitor capmatinib.
Alanazi AZ, Alhazzani K, El-Wekil MM, Ali ABH, Darweesh M, Ibrahim H.
Talanta · journal article · DOI 10.1016/j.talanta.2024.126610Intracranial response to capmatinib after progression on crizotinib in a patient with <i>MET</i> exon 14 skipping non-small cell lung cancer-a case report.
Jóri B, Bundschuh O, Falk M, Heukamp LC, Kluge A, Tiemann M, Willborn KC, Woitzik J, Griesinger F.
Transl Lung Cancer Res · journal article; case reports; case-report · DOI 10.21037/tlcr-23-769Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.
Lara MS, Riess JW, Goldman JW, Jiang F, Bivona TG, Blakely CM.
Clin Lung Cancer · clinical trial protocol; research-article; journal article · DOI 10.1016/j.cllc.2024.07.002Synchronous Double Primary Lung Adenocarcinomas With <i>EGFR</i> L858R Point Mutation and <i>MET</i> Exon 14 Skipping Mutation.
Ando S, Futami S, Azuma K, Nishimatsu K, Shirasaka T, Minami S.
J Med Cases · journal article; case reports; case-report · DOI 10.14740/jmc4210Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a <i>MET</i> exon 14 mutation.
Conci N, Marchiori V, Federico AD, Giglio A, Sperandi F, Melotti B, Gelsomino F.
Per Med · journal article; case reports · DOI 10.1080/17410541.2024.2369493Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
Felip E, Metro G, Soo RA, Wolf J, Solomon BJ, Tan DS, Ardizzoni A, Lee DH, Sequist LV, Barlesi F, Ponce-Aix S, Abreu DR, Campelo MRG, Sprauten M, Djentuh LO, Smith N, Jary A, Belli R, Glaser S, Zou M, Cui X, Giovannini M, Yang JC.
Eur J Cancer · clinical trial, phase ii; multicenter study; clinical trial, phase i; journal article · DOI 10.1016/j.ejca.2024.114182Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
Kron A, Scheffler M, Wiesweg M, Hummel HD, Kulhavy J, Gatteloehner S, Kollmeier J, Schubart C, Groß T, Demes MC, Keymel S, Joosten M, Merkelbach-Bruse S, Wölwer CB, Tufman A, Kauffmann-Guerrero D, Oeser K, Zehaczek M, Jeratsch U, Wolf J.
Eur J Cancer · comparative study; multicenter study; journal article · DOI 10.1016/j.ejca.2024.114158Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy.
Zuckermann M, He C, Andrews J, Bagchi A, Sloan-Henry R, Bianski B, Xie J, Wang Y, Twarog N, Onar-Thomas A, Ernst KJ, Yang L, Li Y, Zhu X, Ocasio JK, Budd KM, Dalton J, Li X, Chepyala D, Zhang J, Xu K, Hover L, Roach JT, Chan KC, Hofmann N, McKinnon PJ, Pfister SM, Shelat AA, Rankovic Z, Freeman BB, Chiang J, Jones DTW, Tinkle CL, Baker SJ.
Mol Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12943-024-02027-6Characterization of MET Alterations in 37 Gastroesophageal Cancer Cell Lines for MET-Targeted Therapy.
Kim JS, Kim MY, Hong S.
Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms25115975Unfavorable response to capmatinib for MET exon14 skipping after first-line osimertinib in a patient with EGFR-mutated lung adenocarcinoma: A case report and literature review.
Araki T, Kanda S, Yazaki T, Hirabayashi T, Komatsu M, Sonehara K, Tateishi K, Hanaoka M.
Respir Investig · review; journal article; case reports · DOI 10.1016/j.resinv.2024.05.009A real-world pharmacovigilance study of FDA adverse event reporting system events for Capmatinib.
Qi Y, Li J, Lin S, Wu S, Chai K, Jiang X, Qian J, Jiang C.
Sci Rep · research-article; journal article · DOI 10.1038/s41598-024-62356-wCapmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non-small cell lung cancer.
Felip E, Metro G, Tan DSW, Wolf J, Mark M, Boyer M, Hughes BGM, Bearz A, Moro-Sibilot D, Le X, Puente J, Massuti B, Tiedt R, Wang Y, Xu C, Mardjuadi FI, Cobo M.
Lung Cancer · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1016/j.lungcan.2024.107820Remarkable response to capmatinib in a patient with intrahepatic cholangiocarcinoma harboring <i>TFG</i>-<i>MET</i> fusion.
Ueta A, Yamada A, Yoshioka M, Kanai M, Muto M, Okita N.
Int Cancer Conf J · research-article; journal article · DOI 10.1007/s13691-024-00664-8A phase Ib/II trial of capmatinib plus spartalizumab <i>vs.</i> spartalizumab alone in patients with pretreated hepatocellular carcinoma.
Santoro A, Assenat E, Yau T, Delord JP, Maur M, Knox J, Cattan S, Lee KH, Del Conte G, Springfeld C, Leo E, Xyrafas A, Fairchild L, Mardjuadi F, Chan SL.
JHEP Rep · research-article; journal article · DOI 10.1016/j.jhepr.2024.101021Response to capmatinib in a patient with neuroendocrine carcinoma of the gallbladder origin harboring <i>MET</i> amplification.
Yamamura S, Kanai M, Takeuchi Y, Okita N, Kondo T, Yoshioka M, Matsubara J, Matsumoto S, Muto M.
Int Cancer Conf J · research-article; journal article · DOI 10.1007/s13691-023-00643-5Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma.
Myint KZ, Sueca-Comes M, Collier P, Balasubramanian B, Venkatraman S, Gordan J, Zaitoun AM, Mukherjee A, Arora A, Larbcharoensub N, Suriyonplengsaeng C, Wongprasert K, Janvilisri T, Gomez D, Grabowska AM, Tohtong R, Bates DO, Yacqub-Usman K.
Front Oncol · research-article; journal article · DOI 10.3389/fonc.2023.1184900Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution.
Schneider JL, Shaverdashvili K, Mino-Kenudson M, Digumarthy SR, Do A, Liu A, Gainor JF, Lennerz JK, Burns TF, Lin JJ.
NPJ Precis Oncol · journal article; case-report · DOI 10.1038/s41698-023-00464-yProfile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives.
Fraser M, Seetharamu N, Diamond M, Lee CS.
Cancer Manag Res · review-article; review; journal article · DOI 10.2147/cmar.s386799Capmatinib-Associated Pseudoacute Kidney Injury in Nonsmall Cell Lung Cancer.
Sandoval L, Radhakrishnan Y, Vaughan LE, Potter A, Mansfield AS, Herrmann SM.
Kidney Int Rep · brief-report; journal article · DOI 10.1016/j.ekir.2023.08.032The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.
Hsu R, Benjamin DJ, Nagasaka M.
Cancers (Basel) · review-article; review; journal article · DOI 10.3390/cancers15143561Capmatinib
Författaruppgift saknas
Journal missing · reviewSevere hepatotoxicity during treatment with capmatinib.
Valencia Soto CM, Martínez Callejo V, García-Avello Fernández-Cueto A, Villacañas Palomares MV, Barbadillo Villanueva S, Ochagavía Sufrategui M, López-Brea Piqueras MF, Valero Domínguez M.
J Oncol Pharm Pract · journal article; case reports · DOI 10.1177/10781552231173120Capmatinib (Tabrecta) for NSCLC.
Författaruppgift saknas
Med Lett Drugs Ther · journal article · DOI 10.58347/tml.2023.1674dResponse to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
Turpin A, Descarpentries C, Grégoire V, Farchi O, Cortot AB, Jamme P.
Oncologist · research-article; journal article; case reports · DOI 10.1093/oncolo/oyac194Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC.
Sun Y, Yang J, Li Y, Luo J, Sun J, Li D, Wang Y, Wang K, Yang L, Wu L, Sun X.
Mol Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s12943-022-01681-yAbsorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite.
Glaenzel U, Jin Y, Hansen R, Schroer K, Rahmanzadeh G, Pfaar U, Jaap van Lier J, Borell H, Meissner A, Camenisch G, Zhao S.
Drug Metab Dispos · clinical trial, phase ii; research support, non-u.s. gov't; journal article · DOI 10.1124/dmd.119.090324